Recent integrative and molecular docking research revealed the important role of enterolactone on breast cancer stem cells through their interaction with several targets (EGFR, Akt1, SMAD 2, SMAD 3, MMP-2, MAPK 8, EZH 2—a histone methyl transferase), the down-regulation of Wnt/β-catenin/PI3/Akt/mTOR signaling pathways, and epigenetic modifications (de-regulated expression of miR-30b, miR-324-5p, miR-382, and miR-423-3p and increased expression of miR-30b and miR-324-5p) [186,187]. This evidence concerns the gene AKT1 and breast carcinoma.